Aprea Therapeutics, Inc. (APRE) Operating cash flow 2017–2025
Aprea Therapeutics, Inc. (APRE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.9MFY2025 · since FY2017: -$14.0M → -$12.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.9M | +4.9% |
| FY2024 | -$13.6M | -11.3% |
| FY2023 | -$12.2M | +51.3% |
| FY2022 | -$25.0M | +33.6% |
| FY2021 | -$37.7M | +9.8% |
| FY2020 | -$41.8M | -56.5% |
| FY2019 | -$26.7M | -75.1% |
| FY2018 | -$15.3M | -8.9% |
| FY2017 | -$14.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More APRE financial trends
APRE RevenueAPRE Net incomeAPRE Net marginAPRE Gross profitAPRE Gross marginAPRE Operating incomeAPRE Operating marginAPRE Free cash flowAPRE Capital expendituresAPRE Return on equityAPRE Stock buybacksAPRE Dividends paidAPRE Total assetsAPRE Total liabilitiesAPRE Shareholders’ equityAPRE overview →